Xenetic Biosciences - 53 Year Dividend History | XBIO
Historical dividend payout and yield for Xenetic Biosciences (XBIO) since 1971. The current TTM dividend payout for Xenetic Biosciences (XBIO) as of November 20, 2024 is $0.00. The current dividend yield for Xenetic Biosciences as of November 20, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Drug Manufacturing |
$0.006B |
$0.003B |
|
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
